Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis

In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical kidney journal 2012-06, Vol.5 (3), p.240-243
Main Authors: Westerberg, Per-Anton, Linde, Torbjörn, Vanderschueren, Dirk, Billen, Jaak, Jans, Ivo, Ljunggren, Östen
Format: Article
Language:English
Subjects:
Clinical Cases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfs031